You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Roll out of intraveneous artesunate under named patient programmes in the Netherlands, Belgium and France
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, September 2013
|
| DOI | 10.1186/1750-1172-8-150 |
| Pubmed ID | |
| Authors |
Annemarie Rosan Kreeftmeijer-Vegter, Cornelis KW van Veldhuizen, Peter J de Vries |
| Abstract |
Intravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, this treatment is only available in a few countries via named patient programmes (NPPs). As a case study, the legal and organisational aspects and pharmacovigilance of these NPPs and possibilities for harmonisation within the EU were studied over time and space using IV artesunate (Malacef) in the Netherlands, Belgium and France. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 20% |
| Mexico | 1 | 20% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 40% |
| Science communicators (journalists, bloggers, editors) | 2 | 40% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 6% |
| Unknown | 16 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 29% |
| Other | 3 | 18% |
| Student > Postgraduate | 3 | 18% |
| Student > Ph. D. Student | 3 | 18% |
| Professor | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 1 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 24% |
| Nursing and Health Professions | 3 | 18% |
| Agricultural and Biological Sciences | 3 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 12% |
| Unknown | 5 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2020.
All research outputs
#7,714,912
of 25,374,917 outputs
Outputs from Orphanet Journal of Rare Diseases
#1,076
of 3,105 outputs
Outputs of similar age
#64,520
of 215,074 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#20
of 51 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 215,074 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.